Clinical Study on the Safety and Efficacy of CD20/CD19 Cell Injection in the Treatment of Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

ConditionsR/R B-NHL Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (R/R B-NHL)

Trial statusNot yet recruiting

Trial phaseNot applicable

Trial typeInterventional

Biological sexAll

Age18-78

SponsorDonghua Zhang

About this trial

Evaluate the safety and tolerability of AcNK-Sup003 cell injection in subjects with relapsed or refractory B-cell non-Hodgkin lymphoma (R/R B-NHL). To preliminarily determine the Maximum Tolerated Dose (MTD) or recommended clinical dose of AcNK-Sup003 cell injection.

Eligibility criteria

Qualifiers

None

Disqualifiers

None

Trial design

Treatments tested in this trial

AcNK-Sup003 cell injection

Treatment groups

28 Participants

are divided into 1 treatment group

Sponsors and collaborators

Donghua Zhang

Lead sponsor

Tongji Hospital

Sponsor institution

Source ClinicalTrials.gov